SCHEMBL6454587

SCHEMBL6454587

CCOC(=O)C(F)(F)c1ccc(-c2ccc(OC)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
GAA P10253 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 1/20 0.46
CES2 O00748 1/20 0.43
ACHE P22303 1/20 0.43
CES1 P23141 1/20 0.43
TSHR P16473 1/20 0.43
LTB4R2 Q9NPC1 1/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20325777 0.95 ALDH1A1 (0.56) ALDH1A1NPC1RAB9APTGDR2GAA
SCHEMBL13199166 0.91 TSHR (0.46) KMT2APOLBTSHRMAPTKDM4E
SCHEMBL13199136 0.85 TSHR (0.49) ALDH1A1POLBTSHRKDM4E
SCHEMBL16595716 0.84 MAPT (0.47) ALDH1A1NPC1RAB9AGAAL3MBTL1
SCHEMBL1171941 0.84 ACSS2 (0.48) ALDH1A1RAB9APOLBMAPTTARBP2
SCHEMBL12014193 0.83 LMNA (0.45) ALDH1A1NPC1RAB9AL3MBTL1KMT2A
SCHEMBL12004031 0.83 CYP1A1 (0.48) ALDH1A1NPC1RAB9AL3MBTL1KMT2A
SCHEMBL11839741 0.82 ALDH1A1 (0.49) ALDH1A1NPC1RAB9AGAAL3MBTL1
SCHEMBL21501143 0.81 CES2 (0.51) ALDH1A1NPC1RAB9APTGDR2GAA
SCHEMBL5003336 0.80 NPSR1 (0.47) GAAKMT2APOLBCES2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852751-B2 Difluorobutyric acid metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-02-08 US disclosed
US-20030139453-A1 Difluorobutyric acid metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-07-24 US disclosed
EP-1265865-A2 DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-12-18 EP disclosed
WO-2001070693-A2 DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139453-A1 Difluorobutyric acid metalloprotease inhibitors DPEP1, TMPRSS15, FAP ALDH1A1 251/4885NPC1 1376/4885RAB9A 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.